日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC

度伐利尤单抗联合放化疗治疗不可切除的III期非小细胞肺癌的真实世界5年疗效

Girard, N; Bar, J; Baas, P; Chouaid, C; Christoph, D C; Field, J K; Fietkau, R; Garassino, M C; Garrido Lopez, P; Gregorc, V; Haakensen, V D; Hiltermann, T J N; Kao, S; McDonald, F; Mornex, F; Moskovitz, M; Peters, S; Siva, S; Solomon, B; Qiao, Y; Anand, S; Chander, P; Shcherbakova, T; Diaz Perez, I; Filippi, A R

Optimisation and validation of line-of-therapy advancement algorithms in advanced/metastatic non-small-cell lung cancer: an I-O Optimise study

晚期/转移性非小细胞肺癌治疗线推进算法的优化与验证:一项 IO Optimise 研究

Lay-Flurrie, S; Greystoke, A; Rault, C; Wolf, A; Riaz, M; Leal, C; de Abreu E Lima, F; Van Naarden Braun, K; Evans-Cheung, T; Glassberg, M B; Eccles, L J; Cheeseman, S; Chouaid, C; Baas, P

Properties of CD8 T-cell-recognized neoantigens in different tumor types

不同肿瘤类型中CD8 T细胞识别的新抗原的特性

Ketelaars, S L C; van Buuren, M M; Gangaev, A; van Rooij, N; Patiwael, S; Hoefakker, K; Fanchi, L F; Baas, P; van der Heijden, M; Kok, M; Schumacher, T N; Kvistborg, P; Haanen, J B A G

Boston biorepository, recruitment and integrative network (BBRAIN): A resource for the Gulf War Illness scientific community

波士顿生物样本库、招募和整合网络(BBRAIN):海湾战争综合症科学界的资源

Keating, D; Zundel, C G; Abreu, M; Krengel, M; Aenlle, K; Nichols, M D; Toomey, R; Chao, L L; Golier, J; Abdullah, L; Quinn, E; Heeren, T; Groh, J R; Koo, B B; Killiany, R; Loggia, M L; Younger, J; Baraniuk, J; Janulewicz, P; Ajama, J; Quay, M; Baas, P W; Qiang, L; Conboy, L; Kokkotou, E; O'Callaghan, J P; Steele, L; Klimas, N; Sullivan, K

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

使用存档肿瘤样本与新采集的肿瘤样本评估PD-L1表达和总生存期:KEYNOTE-010试验的最新分析

Herbst, R S; Baas, P; Perez-Gracia, J L; Felip, E; Kim, D-W; Han, J-Y; Molina, J R; Kim, J-H; Dubos Arvis, C; Ahn, M-J; Majem, M; Fidler, M J; Surmont, V; de Castro, G Jr; Garrido, M; Shentu, Y; Emancipator, K; Samkari, A; Jensen, E H; Lubiniecki, G M; Garon, E B

Controlled before-after intervention study of suburb-wide street changes to increase walking and cycling: Te Ara Mua-Future Streets study design

一项旨在通过郊区街道改造增加步行和骑行的对照前后干预研究:Te Ara Mua-未来街道研究设计

Macmillan, A K; Mackie, H; Hosking, J E; Witten, K; Smith, M; Field, A; Woodward, A; Hoskins, R; Stewart, J; van der Werf, B; Baas, P

Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis

胸部放疗时机对局限期小细胞肺癌的影响:个体患者数据荟萃分析的实用性

De Ruysscher, D; Lueza, B; Le Péchoux, C; Johnson, D H; O'Brien, M; Murray, N; Spiro, S; Wang, X; Takada, M; Lebeau, B; Blackstock, W; Skarlos, D; Baas, P; Choy, H; Price, A; Seymour, L; Arriagada, R; Pignon, J-P

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†

一项随机 II 期研究,比较 MEK1/MEK2 抑制剂曲美替尼 (GSK1120212) 与多西他赛在 KRAS 突变型晚期非小细胞肺癌 (NSCLC) 中的疗效†

Blumenschein, G R Jr; Smit, E F; Planchard, D; Kim, D-W; Cadranel, J; De Pas, T; Dunphy, F; Udud, K; Ahn, M-J; Hanna, N H; Kim, J-H; Mazieres, J; Kim, S-W; Baas, P; Rappold, E; Redhu, S; Puski, A; Wu, F S; Jänne, P A

A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).

一项随机、双盲、II 期研究,评估厄洛替尼联合或不联合舒尼替尼作为转移性非小细胞肺癌 (NSCLC) 二线治疗的疗效

Groen H J M, Socinski M A, Grossi F, Juhasz E, Gridelli C, Baas P, Butts C A, Chmielowska E, Usari T, Selaru P, Harmon C, Williams J A, Gao F, Tye L, Chao R C, Blumenschein G R Jr

[Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]

[欧洲呼吸学会和欧洲胸外科医师学会关于恶性胸膜间皮瘤治疗的指南]

Scherpereel, A; Astoul, P; Baas, P; Berghmans, T; Clayson, H; de Vuyst, P; Dienemann, H; Galateau-Salle, F; Hennequin, C; Hillerdal, G; Le Pe'choux, C; Mutti, L; Pairon, J-C; Stahel, R; van Houtte, P; van Meerbeeck, J; Waller, D; Weder, W